Advertisement
UK markets close in 7 hours 22 minutes
  • FTSE 100

    7,832.08
    -44.97 (-0.57%)
     
  • FTSE 250

    19,275.94
    -174.73 (-0.90%)
     
  • AIM

    740.85
    -4.44 (-0.60%)
     
  • GBP/EUR

    1.1680
    -0.0003 (-0.02%)
     
  • GBP/USD

    1.2444
    +0.0005 (+0.04%)
     
  • Bitcoin GBP

    52,320.64
    +3,115.30 (+6.33%)
     
  • CMC Crypto 200

    1,328.14
    +15.52 (+1.18%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • CRUDE OIL

    83.52
    +0.79 (+0.95%)
     
  • GOLD FUTURES

    2,400.30
    +2.30 (+0.10%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,235.31
    -150.56 (-0.92%)
     
  • DAX

    17,668.08
    -169.32 (-0.95%)
     
  • CAC 40

    7,969.73
    -53.53 (-0.67%)
     

AbbVie Expects Peak Sales of $7 Billion for Imbruvica

AbbVie Expects Peak Sales of $7 Billion for Imbruvica

AbbVie (ABBV) has projected Imbruvica’s annual revenues to reach $5 billion by 2020. The drug has already changed the treatment paradigm in the second line plus CLL segment and for CLL patients with 17p deletion. AbbVie expects that in the future, nearly eight out of ten CLL patients will benefit from an Imbruvica-based therapy at one point or another.